Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
106.3 USD | -0.24% | +0.82% | -13.56% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company has a low valuation given the cash flows generated by its activity.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-13.56% | 6.7B | C+ | ||
+43.64% | 754B | C+ | ||
+39.16% | 630B | B | ||
-6.58% | 352B | C+ | ||
+19.72% | 331B | B- | ||
+8.78% | 298B | C+ | ||
+11.70% | 217B | B- | ||
-1.76% | 216B | A+ | ||
+0.03% | 163B | C+ | ||
+6.13% | 164B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- JAZZ Stock
- Ratings Jazz Pharmaceuticals plc